Official SEC submissions
GSK SEC Filings
Direct answer
GSK's latest SEC filing is 6-K.
Get free GSK email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Recent SEC filings
6-K
Current report
Filed:
Report date:
GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA
6-K
Current report
Filed:
Report date:
RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA
6-K
Current report
Filed:
Report date:
JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC
6-K
Current report
Filed:
Report date:
JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE
6-K
Current report
Filed:
Report date:
MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III
6-K
Current report
Filed:
Report date:
FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN
6-K
Current report
Filed:
Report date:
US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER
144
Planned securities sale
Filed:
6-K
Current report
Filed:
Report date:
NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE
6-K
Current report
Filed:
Report date:
HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ
6-K
Current report
Filed:
Report date:
JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS
6-K
Current report
Filed:
Report date:
BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE
6-K
Current report
Filed:
Report date:
CAMLIPIXANT PHASE III RESULTS UPDATE
6-K
Current report
Filed:
Report date:
GSK COMPLETES ACQUISITION OF NUVALENT, INC
6-K
Current report
Filed:
Report date:
POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER
6-K
Current report
Filed:
Report date:
HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ
Verified data
- Recent filing categories
- 2
- Recent filings
- 40
- SEC CIK
- 0001131399
- Latest filing date
- September 24, 2026